iiinova — where your digital self keeps evolving

Reposted by Paolo Ciracì

The OncoAlert Network 🚨 @oncoalert.bsky.social · 26/05/2026

The OncoAlert🚨 GI faculty’s TOP 10 abstracts In GI Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior experts across #ColorectalCancer #ColonCancer #LiverCancer #PancreaticCancer and more

011 1

Reposted by Paolo Ciracì

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/05/2026

Dear Colleagues, As #ASCO26 descends on Chicago, OncoAlert 🚨 is proud to introduce the OncoAlert PULSE Faculty 🩺 — your frontline team for every breakthrough, every result, every moment. Live. As it happens!

011 1

Reposted by Paolo Ciracì

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/04/2026

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study ascopubs.org/doi/10.1200/...

021 2

Paolo Ciracì @paolociraci.bsky.social · 25/10/2025

Final results of the PARERE Study 🩸 428 mCRC pts screened via liquid biopsy for anti-EGFR re-tx 🧬 >⅓ RAS and/or BRAF mut in ctDNA ❌ No OS diff (pani→rego vs rego→pani) ✅ Higher ORR, DCR & PFS with pani, regardless of sequence doi.org/10.1016/j.anno…

010 1

Paolo Ciracì @paolociraci.bsky.social · 18/10/2025

The final results of the PARERE study by GONO Foundation concomitantly published on Annals of Oncology #ESMO25 @myesmo.bsky.social Open Access 👉 t.co/sTomWwT8Do

t.co

https://www.annalsofoncology.org/article/S0923-7534(25)04934-8/fulltext

010 1

Reposted by Paolo Ciracì

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 04/07/2025

#ESMOGI25: Randomised #ClinicalTrials and real-world studies in #mCRC provide further evidence in favour of anti-EGFR rechallenge, particularly with a prolonged intertreatment interval. Read more in the #ESMODailyReporter 🔗 ow.ly/ZfB450Wl2G8

052 5

Paolo Ciracì @paolociraci.bsky.social · 01/06/2025

First results from the PARERE trial by @FoundationGono 🩸RAS and BRAF ctDNA muts: >1/3 of mCRC patients eligible for anti-EGFR re-treatment ➡️ pani re-tx was associated with higher ORR, DCR, and longer PFS independently of the treatment sequencing #ASCO25 @ascocancer.bsky.social

070 7

Reposted by Paolo Ciracì

American Society of Clinical Oncology @ascocancer.bsky.social · 22/05/2025

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH

01610 16

Paolo Ciracì @paolociraci.bsky.social · 25/05/2025

Our review and evidence-based algorithm on late-line treatment options for metastatic colorectal cancer patients @natrevclinonc.nature.com Full Article 👉 rdcu.be/d0AHE

1142 14